Patient preferences for noninsulin diabetes medications: A systematic review

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 2055-2062

  Purnell, Tanjala S ^a,b   Joy, Susan ^c   Little, Emily ^a   Bridges, John F P ^c   Maruthur, Nisa ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT PREFERENCE; REVIEW; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION; ADULT; DECISION MAKING; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; PATIENT CARE; PROCEDURES; TREATMENT OUTCOME;

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CHOICE BEHAVIOR; DECISION MAKING; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT PREFERENCE; PATIENT-CENTERED CARE; TREATMENT OUTCOME;

EID: 84903538121     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2527     Document Type: Review

References (19)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
2. Bridges JFPOE, Johnson FR, Hauber AB. Patient preference methods - a patient centered evaluation paradigm [Internet], 2007. Available from http://www.ispor.org/news/articles/Dec07/PPM.asp. Accessed 6 September 2013
3. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700
4. Joy SM, Little E, Maruthur NM, Purnell TS, Bridges JF. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics 2013;31:877-892
5. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-384 (Pubitemid 28438523)
6. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD, AHRQ, 2012. (AHRQ publ. no. 10(12)-EHC063-EF)
7. Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment. Curr Med Res Opin 2011;27:2175-2183
8. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-230
9. Brown SE, Meltzer DO, Chin MH, Huang ES. Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. J Am Geriatr Soc 2008;56:1183-1190
10. Chin MH, Drum ML, Jin L, Shook ME, Huang ES, Meltzer DO. Variation in treatment preferences and care goals among older patients with diabetes and their physicians. Med Care 2008;46:275-286
11. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009;26:416-424.
12. Jendle J, Torffvit O, Ridderstråle M, Ericsson A, Nilsen B, Bøgelund M. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. J Media Econ 2012;15(Suppl. 2):1-5
13. Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson A, Bøgelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917-923
14. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-1265 (Pubitemid 47357727)
15. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 2011;13:144-149
16. Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products - liraglutide and exenatide - for the treatment of type 2 diabetes. J Med Econ 2010;13:655-661
17. Dolan JG, Isselhardt BJ, Jr., Cappuccio JD. The analytic hierarchy process in medical decision making: a tutorial.Med Decis Making 1989;9:40-50 (Pubitemid 19034092)
18. Maruthur NM, Joy S, Dolan J, Segal JB, Shihab HM, Singh S. Systematic assessment of benefits and risks: study protocol for a multicriteria decision analysis using the Analytic Hierarchy Process for comparative effectiveness research. F1000Res 2013;2:160
19. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med 2010;153:194-199